Algert Global LLC Makes New $704,000 Investment in Bioventus Inc. (NYSE:BVS)

Algert Global LLC purchased a new position in shares of Bioventus Inc. (NYSE:BVS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 67,020 shares of the company’s stock, valued at approximately $704,000. Algert Global LLC owned 0.08% of Bioventus as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. HighTower Advisors LLC raised its stake in shares of Bioventus by 11.3% in the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after acquiring an additional 1,380 shares during the period. Principal Financial Group Inc. raised its stake in shares of Bioventus by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock valued at $202,000 after acquiring an additional 1,652 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock valued at $36,000 after acquiring an additional 1,786 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Bioventus by 26.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company’s stock valued at $160,000 after purchasing an additional 3,153 shares in the last quarter. Finally, Plato Investment Management Ltd acquired a new stake in Bioventus during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Analysts Set New Price Targets

BVS has been the subject of a number of recent analyst reports. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a “buy” rating in a report on Wednesday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Bioventus Price Performance

BVS opened at $6.70 on Monday. The firm has a market cap of $549.02 million, a price-to-earnings ratio of -10.98 and a beta of 0.95. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a twelve month low of $5.27 and a twelve month high of $14.38. The company has a fifty day simple moving average of $8.40 and a 200 day simple moving average of $10.05.

Insiders Place Their Bets

In other Bioventus news, CFO Mark Leonard Singleton sold 6,498 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. This trade represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,208 shares of company stock valued at $226,138 in the last ninety days. Corporate insiders own 32.90% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.